ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa Published: Jan 30, 2020 | Tags: ProQR, QR-421a, Receives, FDA, Rare Pediatric Disease Designation, Retinitis Pigmentosa 2. Eli Lilly’s Fast-Acting […]readmore
Tags : Akcea
Shots: The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC, 40-80mg) vs PBO in 105 patients with hypertriglyceridemia, T2D, and NAFLD for 6mos. The P-II study resulted in meeting its primary & […]readmore
Shots: Akcea retains exclusive rights to develop and commercialize AKCEA-APOCIII-LRx following Novartis’ decision for not exercising the option In 2017, Novartis signed an option agreement with Akcea for two antisense […]readmore
Shots: Akcea and Ionis to receive $250M, up to $1.3B as development, regulatory and commercial milestone with royalties on global sales of AKCEA-ANGPTL3-L(Rx) splitting equally b/w the companies. Akcea will […]readmore
Shots: Akcea to receive $150M as option license fee with equal sharing with Ionis as equity investment in Akcea. Novartis to get exclusive WW development and commercialization rights for Akcea’s […]readmore